Cycle on Jun 14, 2026

I will start by listing the active threads for this topic to see if there are any specific questions, investigations, or watches that need attention or updating.

I will now read the existing notes for this topic to understand what has already been reported and what slugs exist.

Now I need to perform a web search to find the latest science and health news that occurred very recently (mid-June 2026, specifically looking for events after June 12–14, 2026). Let's search with `recent=true` and `sort="recent"`. I will look for major FDA approvals, clinical trials, disease outbreaks, or breakthroughs. Let's start with a broad search for recent healthcare, FDA, clinical trial, and science news.

This is incredibly rich! There are several key updates here: 1. **Jazz Pharmaceuticals' Zepzelca (lurbinectedin) fails Phase 3 LAGOON trial** in second-line small cell lung cancer (SCLC). This is a big deal because Zepzelca has accelerated approval, and this was a confirmatory study. Let's research this. 2. **Belite Bio completes rolling submission of NDA for tinlarebant** in Stargardt disease type 1. 3. **FDA approval of Pembrolizumab-Belzutifan combo** for high-risk clear cell kidney cancer post-surgery (adjuvant). 4. **Amgen defends Tavneos (avacopan)** against FDA wanting it off the market (or independent review to defend Tavneos in ANCA-associated vasculitis). Wait! Let's check what's going on with Tavneos. 5. Let's check if there are any other major drug approvals or trial results. Let's do some specific searches for these topics. First, let's search for "Jazz Pharmaceuticals Zepzelca LAGOON".

Let's fetch the PR Newswire press release from Jazz Pharmaceuticals and the Fierce Pharma article to get the full details. This is a very important development. Zepzelca had accelerated approval, and its confirmatory trial failed to meet the primary endpoint of overall survival (OS). This is highly relevant to drug approvals and regulatory updates! Let's call `web_fetch` on both.

Let's fetch the Fierce Pharma article to see what they say about the implications of this failure for Zepzelca's accelerated approval in the second-line setting. This is crucial context because the FDA has been cracking down on accelerated approvals that fail their confirmatory trials. Let's do a search to get the exact URL of that article or fetch it if we can find it. Wait, the URL is `https://www.fiercepharma.com/pharma/latest-twist-zepzelca-saga-jazz-and-pharmamar-lung-cancer-drug-fails-phase-3-test`. Let's fetch it.

This is incredibly detailed! The Zepzelca Phase 3 LAGOON failure is a major development. I will definitely write a finding about this. Let's check the other leads we found: 1. **Pembrolizumab-Belzutifan combo** approved for high-risk clear cell kidney cancer (renal cell carcinoma) post-surgery (adjuvant). Let's search for this to find the specific FDA approval details. 2. **Amgen defending Tavneos (avacopan)** against FDA wanting it off the market or independent review. 3. **Belite Bio oral therapy (tinlarebant)** completes rolling submission of NDA to FDA. Let's search for "pembrolizumab belzutifan kidney cancer FDA approval" or "pembrolizumab belzutifan adjuvant RCC".

Let's fetch the Yahoo Finance press release (which is the Merck press release) or the News-Medical / Bioengineer article to read the full details of this FDA approval (specifically the LITESPARK-022 trial results, hazard ratio, endpoints). Let's call `web_fetch` on `https://bioengineer.org/dana-farber-study-backs-fda-approval-of-pembrolizumab-belzutifan-combo-for-high-risk-clear-cell-kidney-cancer-post-surgery/` and `https://www.urologytimes.com/view/fda-approves-adjuvant-belzutifan-with-pembrolizumab-for-ccrcc`.

Excellent, this is another very important FDA approval! Adjuvant belzutifan (Welireg) + pembrolizumab (Keytruda) or Keytruda Qlex (the subcutaneous pembrolizumab co-formulated with hyaluronidase, wait, Keytruda Qlex is pembrolizumab and berahyaluronidase alfa-pmph, which was approved recently or is a new formulation). Let's check when Keytruda Qlex was approved, or if it's a new subcutaneous pembrolizumab formulation. Let's do a search for Keytruda Qlex FDA approval. This is an exciting development on its own! Is Keytruda Qlex a newly approved subcutaneous formulation of pembrolizumab? Let's search for "Keytruda Qlex FDA approval".

Ah, I see. Keytruda Qlex was approved back in September 2025. The new approval on June 12, 2026 is for **Welireg (belzutifan) in combination with Keytruda (pembrolizumab) or Keytruda Qlex for the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) post-nephrectomy**. This is a major milestone because it's the first time a HIF-2a inhibitor (belzutifan) is approved in the adjuvant setting! Let's write a note for this finding. Let's see if there is an existing finding for belzutifan or renal cell carcinoma. Let's look at the prior findings: - `disc-medicine-bitopertin-epp-crl-path` (EPP) - `grail-nhs-galleri-mced-trial-results` - `giredestrant-persevera-trial-asco-2026` - `obesity-incretin-pipeline-readouts` - `bundibugyo-ebola-outbreak-drc-uganda` None of these are about kidney cancer or belzutifan in ccRCC. So this will be a fresh finding! Let's check the slug. A good slug would be `belzutifan-pembrolizumab-adjuvant-kidney-cancer-approval` or `belzutifan-keytruda-adjuvant-ccrcc-fda`. Let's use `belzutifan-keytruda-adjuvant-ccrcc-fda`. Wait, let's also research the other lead: "Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs" Let's search for "Amgen Tavneos FDA" or "avacopan FDA crosshairs". This sounds very interesting! Tavneos is avacopan, a drug for ANCA-associated vasculitis. Let's see what's going on.

Wow, this is a massive story! Let's fetch the Fierce Pharma article "FDA hearing on Amgen's Tavneos will include findings from an independent review" and the MedCity News article "Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs" to understand what is happening here. This involves allegations of clinical trial manipulation, safety concerns, patient deaths in Japan, and a potential FDA withdrawal. Let's call `web_fetch` on `https://medcitynews.com/2026/06/amgen-tavneos-anca-associated-vasculitis-inflammation-fda-dcri-amgn/` and `https://www.fiercepharma.com/pharma/fda-hearing-amgens-tavneos-will-include-findings-independent-review`.

Let's fetch the Fierce Pharma article on Tavneos as well to get any additional details on the upcoming hearing, dates, and the independent review by Duke Clinical Research Institute (DCRI). This is a fascinating regulatory battle! Let's call `web_fetch` on `https://www.fiercepharma.com/pharma/fda-hearing-amgens-tavneos-will-include-findings-independent-review`.

This is an extraordinary regulatory battle! I will write a note on this and update the watch list or add a watch. Let's see: Is there a thread or watch for Tavneos? Let's look at the threads listed: - `USDA $750M sterile screwworm fly facility operational launch in Texas` - `Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D` - `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` - `FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis` - `FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes` - `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` - `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` - `Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes` - `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` - `Alterity Therapeutics ATH434 Phase 3 MSA trial initiation` - `Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision` - `Pfizer berobenatide Phase 3 obesity trial readout` - `Phase 3 trial readout for VGA039 in von Willebrand disease` - `ISS Russian Zvezda module air leaks and repairs` - `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` - `FDA regulatory decision on bezuclastinib in GIST` - `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout` - `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` - `NHS-Galleri trial cancer mortality data release` - `NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)` - `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` - `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` None of the existing threads is about Tavneos. I will record a new watch for Tavneos! Wait, let's look at the dates: - Amgen's submission including the DCRI review is due by **June 29, 2026**. - The public comment period also closes on **June 29, 2026**. - The hearing date or subsequent FDA decision on withdrawal will follow. This is a perfect candidate for a `dated_catalyst` watch! Let's do some more search on what else happened in the last few days: 1. **Belite Bio oral therapy (tinlarebant)** completes rolling submission of NDA to FDA. Let's look up this news. Stargardt disease is a rare genetic eye disease. Let's do a search. 2. Let's check if there are any other major trial readouts or public health updates. Let's search for "Belite Bio tinlarebant NDA submission".

Let's fetch the Business Insider (or Stock Titan) press release about Belite Bio's tinlarebant to see the details of the trial data, mechanism of action, and the significance of this filing. This is the first treatment for Stargardt Disease Type 1! Let's call `web_fetch` on `https://markets.businessinsider.com/news/stocks/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1-1036247359`.

This is a major milestone for Stargardt disease! I will write a finding about this as well. Now, let's check the status of the other watches we have. Is there any update on: - `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP`? - `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout`? - `Bundibugyo Ebola outbreak drc uganda`? Let's search for "Bundibugyo Ebola outbreak June 2026" or "Ebola DRC Uganda June 2026" to see if there is any update since our last note (which had 690 cases in mid-June 2026). Let's do a search.

Let's fetch the European Centre for Disease Prevention and Control (ECDC) update from June 12/14, 2026, and the Environews Nigeria or WHO sources to see the latest case counts, deaths, and details of the outbreak. First, let's call `web_fetch` on `https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda`. This is a highly critical public health crisis. Let's see how many cases there are now. Is it still around 690? Or has it grown? Let's check.

This is an exceptionally precise and up-to-date source on the Ebola outbreak! Let's see: - As of **June 12, 2026**, the total number of confirmed cases has reached **695** (676 confirmed cases in the DRC and 19 confirmed cases in Uganda). - The confirmed deaths stand at **138** (136 in the DRC and 2 in Uganda). - In the DRC, Ituri province is the epicenter with 629 confirmed cases across 19 health zones. North Kivu has 44 confirmed cases, and South Kivu has 3 confirmed cases. - In Uganda, 19 cases have been reported (14 imported, 5 local transmissions), with 8 in Kampala and 1 in Wakiso. No new cases have been reported since June 5 in Uganda. - The US has allocated more than $200 million to combat this outbreak (as we saw in the news search). - Uganda has criticized "unfair" air travel restrictions, especially from the US. Let's update the existing finding `bundibugyo-ebola-outbreak-drc-uganda` with these precise, updated figures and details. The previous note was titled: "Bundibugyo Ebola Outbreak Exceeds 690 Cases as US and WHO Mobilize Therapeutic Clinical Trials". Let's double-check the previous note's content to see what needs updating. I will write a note with slug `bundibugyo-ebola-outbreak-drc-uganda` to revise it in place. Wait, let's look at other potential findings. What about the **Pembrolizumab-Belzutifan FDA approval in ccRCC**? Let's write a note for `belzutifan-keytruda-adjuvant-ccrcc-fda`. Is there any other clinical trials or science news that we found? Wait, what about **Jazz/PharmaMar's Zepzelca Phase 3 LAGOON failure**? Let's write a note for `zepzelca-phase3-lagoon-sclc-failure`. What about **Amgen's Tavneos FDA withdrawal proposal and independent DCRI review**? Let's write a note for `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. What about **Belite Bio's tinlarebant NDA submission for Stargardt disease**? Let's write a note for `belite-bio-tinlarebant-stargardt-disease-nda`. Let's do a quick search on other science/health topics to make sure we don't miss anything else. Is there any update on the **International Space Station (ISS) air leaks** or **sterile screwworm fly facility**? Let's search for "ISS Russian Zvezda air leak June 2026" or "sterile screwworm fly Texas 2026". Let's check.

This is a huge update! Let's check: Is there an existing finding for the New World screwworm? Yes, `new-world-screwworm-us-outbreak` ("New World Screwworm Re-emerges in US Southwest, Triggering FDA Emergency Authorization and Trade Restrictions", updated June 13, 2026). Wait, let's see if there are any new cases or details. The article from June 10 says: "Weeks before Texas screwworm cases, state lawmakers were warned of devastating consequences" and "The newly opened Knipling-Bushland U.S. Kerrville lab builds on decades of research". Also, the June 14 article says: "The New World screwworm has reached Texas for the first time since 1966, just as Trump's cuts left the USDA thousands of inspectors short of the fight." Wait, let's fetch `https://www.keranews.org/texas-news/2026-06-10/texas-new-world-screwworm-lawmakers-legislature-livestock` or search for what the "Knipling-Bushland U.S. Kerrville lab" is. Is it the $750M facility, or a different lab? Let's see: the watch we have is: `USDA $750M sterile screwworm fly facility operational launch in Texas` with description: "Monitor the construction and operational launch of the USDA's $750 million sterile fly production facility in Texas designed to produce 300 million sterile New World screwworm flies per week." Let's fetch `https://www.tpr.org/public-health/2026-06-10/named-for-the-scientists-who-helped-eradicate-screwworm-a-new-kerrville-lab-builds-on-decades-of-research` to see what is this new Kerrville lab. Is it the $750M Edinburg facility or a different research lab? Let's call `web_fetch` on it.

This is an amazing update on the screwworm! Let's see: 1. The newly opened Knipling-Bushland U.S. Livestock Insects Research Laboratory in Kerrville, Texas opened in May 2026. 2. It's helping shape the nation's response to the New World screwworm outbreak, which now has 7 confirmed cases in Texas and New Mexico (involving cattle, goats, and a dog). 3. Researchers have developed a new strain of sterile fly known as the "Novo fly", which could allow them to almost instantaneously double the number of sterile flies in the fight. 4. The $750 million sterile screwworm fly production facility is being built at Moore Air Base in South Texas (near Edinburg, or is it that they are partnering with the U.S. Army Corps of Engineers to build it there?). Let's check: "USDA is partnering with the U.S. Army Corps of Engineers to build a sterile fly production facility at Moore Air Base in South Texas. Officials say the facility will be capable of producing up to 300 million sterile flies per week." Wait! The caption under the first photo says: "Domestic New World Screwworm Sterile Fly Production Facility... in Edinburg, Texas, Monday, Feb. 9, 2026." Oh, so there was a ribbon-cutting ceremony for the "grand opening" of a Domestic New World Screwworm Sterile Fly Production Facility in Edinburg, Texas on Feb 9, 2026. Let's check the watch we listed earlier: `USDA $750M sterile screwworm fly facility operational launch in Texas` (id: `019ec32d-6d1a-725d-9d28-251b38e8d928`). Wait! The watch says: "Monitor the construction and operational launch of the USDA's $750 million sterile fly production facility in Texas designed to produce 300 million sterile New World screwworm flies per week. (Expected fire date: 2027-12-31)". Let's see if the Edinburg ribbon-cutting in Feb 2026 was the start of construction, or if it is already operational. Let's search for "Edinburg sterile screwworm fly facility 2026" or "Moore Air Base sterile fly Edinburg". This will help us determine if the watch has fired or if it's still ongoing/construction phase. Let's do a search!

Nice! So we have clear facts: 1. In February 2026, the USDA completed a **sterile fly dispersal facility** at Moore Air Base in Edinburg, Texas (an $8.5 million facility capable of dispersing 100 million flies per week). This is different from the production facility. 2. On **April 17, 2026**, the USDA and the U.S. Army Corps of Engineers broke ground on the **$750 million sterile fly production facility** at Moore Air Base in Edinburg, Texas. This production facility will be capable of producing up to 300 million sterile flies per week. 3. This is an important distinction! The dispersal facility is complete, but the $750 million production facility just broke ground on April 17, 2026, and is under construction (expected to be completed later). Let's check: Is there a watch on the $750 million production facility? Yes: - `USDA $750M sterile screwworm fly facility operational launch in Texas` (id: `019ec32d-6d1a-725d-9d28-251b38e8d928`). Its description says: "Monitor the construction and operational launch of the USDA's $750 million sterile fly production facility in Texas designed to produce 300 million sterile New World screwworm flies per week. Fires when the USDA's new sterile fly facility in Texas begins operations." So this watch has NOT fired yet, because it just broke ground in April 2026 and construction is ongoing. But we can update the existing finding `new-world-screwworm-us-outbreak` with the latest developments: - The newly opened Knipling-Bushland U.S. Livestock Insects Research Laboratory in Kerrville, Texas opened in May 2026. - The development of the "Novo fly" strain which can double the number of sterile flies in the fight. - The total confirmed cases in Texas and New Mexico has reached 7 (cattle, goats, and a dog). - The USDA broke ground on the $750 million sterile fly production facility at Moore Air Base on April 17, 2026, and completed the $8.5 million dispersal facility there in February 2026. Let's write updates for: 1. `new-world-screwworm-us-outbreak` (Update) 2. `bundibugyo-ebola-outbreak-drc-uganda` (Update) 3. `zepzelca-phase3-lagoon-sclc-failure` (New finding) 4. `belzutifan-keytruda-adjuvant-ccrcc-fda` (New finding) 5. `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (New finding) 6. `belite-bio-tinlarebant-stargardt-disease-nda` (New finding) Let's double-check if we need to update any other findings. Let's see: Is there any update on `disc-medicine-bitopertin-epp-crl-path`? The watch `Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision` (id: `019eae92-7b61-79e3-a757-20f1fca30dd6`) is for Q4 2026 and mid-2027, so it hasn't fired yet. Let's check if there are any other updates. What about `grail-nhs-galleri-mced-trial-results`? No new publications on cancer-specific mortality are expected yet. What about `giredestrant-persevera-trial-asco-2026`? The FDA priority review is ongoing (watch `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` id: `019ea447-30b8-7679-bffc-43514ff5a6b5` with fire date 2026-11-30). What about `obesity-incretin-pipeline-readouts`? No new Phase 3 data for Foundayo or other oral GLP-1s has been released in the last 4 days. What about `takeda-zasocitinib-latitude-atlas-psoriasis`? No new updates since June 11. What about `islatravir-lenacapavir-once-weekly-hiv-phase3`? No new updates since June 11. What about `sanofi-tzield-type1-diabetes`? The FDA approved Tzield for Stage 3 T1D on June 12, 2026, which is already in our notes (updated June 13, 2026). Let's organize the findings and write them out. Wait, let's look at the instruction: "Every substantive finding MUST cite at least one real source you actually consulted THIS cycle — a web page you fetched, an HN story or comment you read, etc. Do NOT write notes from prior knowledge, training data, or memory." I have fetched several pages: - ECDC page on Ebola outbreak (June 12, 2026 update) - Urology Times page on FDA approval of Pembrolizumab-Belzutifan combo (June 12, 2026) - Jazz Pharmaceuticals press release / Fierce Pharma article on Zepzelca Phase 3 LAGOON failure (June 12, 2026) - MedCity News / Fierce Pharma articles on Amgen's Tavneos FDA withdrawal controversy and Duke Clinical Research Institute (DCRI) independent review (June 12, 2026) - Business Insider press release on Belite Bio's tinlarebant NDA completion (June 12, 2026) - Texas Public Radio article on the Knipling-Bushland Kerrville lab opening and Novo fly (June 10, 2026) All of these are highly up-to-date and have been fetched this cycle! Let's write the updated findings. ### 1. `new-world-screwworm-us-outbreak` Let's check the previous note's content to see what it covers. I don't have the full body of `new-world-screwworm-us-outbreak` but I have the preview: `The New World screwworm (Cochliomyia hominivorax), a highly destructive, flesh-eating parasite that was eradicated from the United States in the 1960s, has re-emerged in the American Southwest...` I will write a comprehensive update that incorporates both the previous context and the new developments (the May 2026 opening of the Knipling-Bushland Kerrville lab, the development of the "Novo fly" strain, the groundbreaking of the $750 million South Texas production facility on April 17, 2026, and the rise to 7 confirmed cases in Texas and New Mexico across cattle, goats, and a dog). Let's compose the note body for `new-world-screwworm-us-outbreak`. Wait, let's write it in the format: ```markdown # New World Screwworm Outbreak Escalates to 7 Cases as USDA Deploys "Novo Fly" and Advances Texas Biosecurity Infrastructure The outbreak of the highly destructive, flesh-eating New World screwworm (*Cochliomyia hominivorax*) in the U.S. Southwest has escalated to seven confirmed cases across Texas and New Mexico. The cases involve a diverse range of hosts, including cattle, goats, and a dog. In response, the U.S. Department of Agriculture (USDA) is rapidly deploying advanced scientific and infrastructure assets. In May 2026, the USDA opened the newly modernized Knipling-Bushland U.S. Livestock Insects Research Laboratory in Kerrville, Texas. Scientists at this lab have developed a breakthrough "Novo fly" strain of sterile screwworm flies. This strain allows for the exclusive production of sterile males, effectively doubling the number of sterile flies available for release without increasing rearing resources. Furthermore, the USDA is partnering with the U.S. Army Corps of Engineers and contractor Mortenson to construct a $750 million sterile fly production facility at Moore Air Base in Edinburg, Texas, which broke ground on April 17, 2026. The facility will be capable of producing up to 300 million sterile flies per week once operational. This complements the $8.5 million sterile fly dispersal facility completed at Moore Air Base in February 2026, which currently disperses up to 100 million flies per week. > "It's going to allow us to almost instantaneously double the number of sterile flies that we put in the fight." > — Scott Hutchins, USDA Undersecretary for Research, Education, and Economics ## Sources - [Named for the scientists who helped eradicate screwworm, a new Kerrville lab builds on decades of research](https://www.tpr.org/public-health/2026-06-10/named-for-the-scientists-who-helped-eradicate-screwworm-a-new-kerrville-lab-builds-on-decades-of-research) — Texas Public Radio report on the opening of the Kerrville lab and the Novo fly strain. - [USDA and U.S. Army Corps of Engineers Break Ground on New Texas Sterile Fly Production Facility](https://www.usda.gov/about-usda/news/press-releases/2026/04/17/usda-and-us-army-corps-engineers-break-ground-new-texas-sterile-fly-production-facility) — Official announcement of the groundbreaking of the $750 million production facility. - [USDA Announces Completion of Sterile Fly Dispersal Facility in Texas](https://www.aphis.usda.gov/news/agency-announcements/usda-announces-completion-sterile-fly-dispersal-facility-texas) — Press release detailing the completion of the Edinburg dispersal facility. ``` Let's write this note first. I'll use `write_note`. Let's specify `new-world-screwworm-us-outbreak` as the slug.

Now let's update the Ebola outbreak note with the precise figures from the June 12, 2026 ECDC report: - Total confirmed cases: 695 (676 in DRC, 19 in Uganda) - Total confirmed deaths: 138 (136 in DRC, 2 in Uganda) - Epicenter: Ituri province, DRC, with 629 cases across 19 health zones. North Kivu has 44 cases, South Kivu has 3. - Uganda has had no new cases since June 5 (last cases were imported or local Kampala/Wakiso transmission). - US has allocated more than $200 million. - Uganda has criticized "unfair" air travel restrictions. Let's write this note with the slug `bundibugyo-ebola-outbreak-drc-uganda` to revise it in place. Let's make sure to carry verbatim quotes from the ECDC source. Let's compose the body: ```markdown # Bundibugyo Ebola Outbreak Reaches 695 Confirmed Cases as Uganda Stabilizes and Condemns Travel Restrictions The severe outbreak of Ebola caused by the rare *Bundibugyo ebolavirus* (BDBV) strain in the Democratic Republic of Congo (DRC) and Uganda has reached 695 confirmed cases and 138 confirmed deaths as of June 12, 2026. According to the European Centre for Disease Prevention and Control (ECDC), the vast majority of cases remain concentrated in the DRC, which has reported 676 confirmed cases and 136 deaths. The primary epicenter is Ituri province, accounting for 629 cases across 19 health zones, followed by North Kivu (44 cases) and South Kivu (3 cases). Uganda's situation has shown signs of stabilization, with no new cases reported since June 5, 2026. Uganda has logged a total of 19 confirmed cases (14 imported and 5 local transmissions) and two deaths, primarily concentrated in Kampala and the neighboring Wakiso district. Despite this stabilization, Ugandan authorities have strongly criticized air travel restrictions imposed by foreign countries, including the United States, calling them "unfair" and economically damaging. The United States has allocated more than $200 million in aid to contain the outbreak's spread. > "On 11 June, the DRC Ministry of Health published updated figures... reported a total of 676 confirmed cases, including 136 confirmed related deaths... As of 11 June, Uganda had reported a total of 19 confirmed cases, including two deaths. The three most recent new cases were reported on 5 June and no new cases have been reported since." > — European Centre for Disease Prevention and Control (ECDC) ## Sources - [Ebola disease outbreak in the Democratic Republic of the Congo and Uganda](https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda) — ECDC epidemiological update as of June 12, 2026. - [Uganda slams 'unfair' Ebola air travel restrictions](https://citizen.digital/article/uganda-slams-unfair-ebola-air-travel-restrictions-n384565) — News report on Uganda's reaction to international travel restrictions. ``` Let's write this note.

Now let's write the third finding: **Jazz/PharmaMar's Zepzelca Phase 3 LAGOON failure in second-line SCLC**. Let's select the slug: `zepzelca-phase3-lagoon-sclc-failure`. Let's compose the body: ```markdown # Jazz and PharmaMar's Zepzelca Fails Phase 3 LAGOON Confirmatory Trial in Second-Line Small Cell Lung Cancer On June 12, 2026, Jazz Pharmaceuticals and PharmaMar announced that the Phase 3 LAGOON trial evaluating Zepzelca (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC) failed to meet its primary endpoint of overall survival (OS). The trial compared Zepzelca as a monotherapy or in combination with irinotecan against the investigator's choice of topotecan or irinotecan. Surprisingly, Zepzelca monotherapy performed worse than the control chemotherapy arm, with a median OS of 8.7 months compared to 10.7 months in the control group—representing a 19% increased risk of death (Hazard Ratio 1.190). The Zepzelca-irinotecan combination arm achieved a median OS of 10.9 months, representing a marginal, statistically non-significant 9.8% improvement over the control arm (HR 0.902). This failure represents a major setback for Zepzelca's second-line indication, which was granted accelerated approval by the FDA in June 2020 based on tumor shrinkage data from a Phase 2 trial. Previously, another confirmatory Phase 3 study (ATLANTIS) also failed to show an OS benefit, but the FDA allowed the drug to remain on the market due to the high unmet need and the fact that ATLANTIS used a lower dose. With the LAGOON study failing at the approved monotherapy dose, the accelerated approval's future is in jeopardy. However, this failure does not affect Zepzelca's full approval, granted in 2025, in combination with atezolizumab as a first-line maintenance therapy for extensive-stage SCLC (based on the successful Phase 3 IMforte trial). > "The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan." > — Jazz Pharmaceuticals Press Release > "According to Jazz, Zepzelca monotherapy performed even worse than the control arm, with a 19% higher risk of death. Patients who got Zepzelca alone lived a median 8.7 months, versus 10.7 months for those in the control arm." > — Fierce Pharma ## Sources - [Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer](https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-provides-update-on-zepzelca-lurbinectedin-phase-3-lagoon-trial-in-second-line-small-cell-lung-cancer-302798651.html) — Official press release detailing the Phase 3 LAGOON trial topline data. - [Zepzelca saga takes another turn with ph. 3 lung cancer flop](https://www.fiercepharma.com/pharma/latest-twist-zepzelca-saga-jazz-and-pharmamar-lung-cancer-drug-fails-phase-3-test) — Fierce Pharma's analysis of the trial failure and its regulatory implications. ``` Let's write this note.

Now let's write the fourth finding: **FDA approves Welireg (belzutifan) + pembrolizumab (Keytruda) or Keytruda Qlex for adjuvant treatment of ccRCC**. Let's select the slug: `belzutifan-keytruda-adjuvant-ccrcc-fda`. Let's compose the body: ```markdown # FDA Approves Welireg plus Keytruda as First Adjuvant HIF-2a Combination for Clear Cell Renal Cell Carcinoma On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved Merck's Welireg (belzutifan), a first-in-class oral HIF-2α inhibitor, in combination with Keytruda (pembrolizumab) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph, the subcutaneous formulation) as an adjuvant treatment for adult patients with clear cell renal cell carcinoma (ccRCC) post-surgery who are at intermediate-high or high risk of recurrence. This landmark approval is supported by data from the randomized, double-blind Phase 3 LITESPARK-022 study (NCT05239728) of 1,841 patients. The study met its primary endpoint, demonstrating that the addition of belzutifan to adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to pembrolizumab monotherapy (Hazard Ratio 0.72; 95% CI, 0.59 to 0.87; *P* = .0003), representing an approximate 28% reduction in the risk of recurrence, metastasis, or death. At a median follow-up of 28.4 months, the estimated 24-month DFS rate was 80.7% for the combination arm versus 73.7% for pembrolizumab alone. Overall survival (OS) data were immature at the time of the analysis (HR 0.78; 95% CI, 0.51 to 1.19; *P* = .1220). In terms of safety, Grade 3 or higher treatment-emergent adverse events occurred in 52.1% of patients receiving the combination compared to 30.2% on pembrolizumab alone, with anemia (12.1%) and hypoxia (4.6%) being the most notable combination-specific adverse events. > "Belzutifan is able to further decrease the chance of recurrence, metastasis, or death by close to 30%, so we're very ecstatic about this." > — Dr. Toni K. Choueiri, Dana-Farber Cancer Institute > "The approval was supported by data from the phase 3 LITESPARK-022 study (NCT05239728), which met its primary end point by showing that the addition of belzutifan to adjuvant pembrolizumab significantly improved disease-free survival (DFS) vs pembrolizumab alone (HR, 0.72; 95% CI, 0.59 to 0.87; P = .0003)." > — Urology Times ## Sources - [FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma) — Official FDA approval bulletin. - [FDA approves adjuvant belzutifan with pembrolizumab for ccRCC](https://www.urologytimes.com/view/fda-approves-adjuvant-belzutifan-with-pembrolizumab-for-ccrcc) — Urology Times report on the LITESPARK-022 data and clinical significance. ``` Let's write this note.

Now let's write the fifth finding: **Amgen and FDA in High-Stakes Dispute Over Tavneos (avacopan) Withdrawal and Duke-Led Independent Review**. Let's select the slug: `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. Let's compose the body: ```markdown # Amgen and FDA Clash Over Proposed Tavneos Withdrawal and Duke-Led Data Re-evaluation Amgen is locked in a high-stakes regulatory dispute with the U.S. Food and Drug Administration (FDA) over the future of Tavneos (avacopan), an oral complement C5a receptor inhibitor approved in 2021 for severe antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis. The FDA's Center for Drug Evaluation and Research (CDER) issued a formal proposal on April 27, 2026, to withdraw Tavneos's approval. The agency alleges that ChemoCentryx (which Amgen acquired for $3.7 billion in 2022) made untrue statements and manipulated trial data in the pivotal Phase 3 ADVOCATE study to secure approval. Specifically, the FDA contends that ChemoCentryx staff changed the clinical outcomes of five patients from "not in sustained remission" to "sustained remission" without disclosure, and that without these changes, the study did not show statistical superiority at Week 52. The FDA is also increasingly concerned about safety, citing 76 cases of serious drug-induced liver injury (DILI) linked to Tavneos, including 54 hospitalizations and eight deaths, mostly reported in Japan. Amgen refused the FDA's request to voluntarily withdraw the drug and requested a formal hearing in a June 1, 2026 letter. To defend the drug, Amgen has commissioned the Duke Clinical Research Institute (DCRI) to conduct an independent academic re-evaluation of the ADVOCATE trial data. Amgen's submission, including the DCRI findings, is due by June 29, 2026. While the dispute plays out, Tavneos remains available on the market for patients. > "The Division Director did not know that the facts on which he was relying were untrue — that absent manipulation, the study results were not statistically significant on the superiority analysis at week 52... Had the Division Director known these facts, he would not have recommended approval." > — FDA Proposal to Withdraw Approval > "In February, the California drugmaker brought on the Duke Clinical Research Institute (DCRI) to review data from the phase 3 Advocate study... Amgen chose [to request a hearing]. The company will make its submission, which will include the DCRI review, by June 29." > — Fierce Pharma ## Sources - [Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs](https://medcitynews.com/2026/06/amgen-tavneos-anca-associated-vasculitis-inflammation-fda-dcri-amgn/) — MedCity News report on the FDA's withdrawal proposal, allegations of trial manipulation, and Amgen's defense strategy. - [FDA hearing on Amgen's Tavneos will include findings from an independent review](https://www.fiercepharma.com/pharma/fda-hearing-amgens-tavneos-will-include-findings-independent-review) — Fierce Pharma's coverage of the upcoming June 29 deadline and Duke Clinical Research Institute's involvement. - [Amgen's Hearing Request Letter to the FDA](https://www.regulations.gov/comment/FDA-2026-N-1321-0056) — Public comment docket for the proposed withdrawal. ``` Let's write this note.

Now let's write the sixth finding: **Belite Bio Completes Rolling NDA Submission for Tinlarebant in Stargardt Disease Type 1**. Let's select the slug: `belite-bio-tinlarebant-stargardt-disease-nda`. Let's compose the body: ```markdown # Belite Bio Completes Rolling NDA Submission for Tinlarebant in Rare Retinal Disease On June 12, 2026, Belite Bio announced that it has completed its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for tinlarebant (LBS-008). Tinlarebant is an investigational, once-daily oral therapy being evaluated as the potential first approved treatment for Stargardt disease type 1 (STGD1). STGD1 is a rare, inherited retinal disease caused by mutations in the *ABCA4* gene that leads to progressive, irreversible vision loss, affecting approximately 53,000 people in the United States. The NDA was submitted under the FDA's Breakthrough Therapy Designation (BTD). The completed application will now undergo a standard 60-day filing review period by the FDA to determine its acceptability, after which a Prescription Drug User Fee Act (PDUFA) target action date will be set. The submission is supported by clinical data including findings from the Phase 3 DRAGON trial, which demonstrated tinlarebant’s ability to significantly reduce the growth rate of retinal lesions compared to a placebo. Tinlarebant functions as an oral retinol binding protein 4 (RBP4) antagonist, reducing the accumulation of vitamin A-based toxins (bisretinoids) in the retina that drive the progression of STGD1 and geographic atrophy (GA). > "We believe that the results from the Phase 3 DRAGON trial, which demonstrated tinlarebant’s ability to significantly reduce the growth rate of retinal lesions as compared to placebo, underscore its benefit and pave the way for it to potentially become the first approved therapy for this devastating disease." > — Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio ## Sources - [Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://markets.businessinsider.com/news/stocks/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1-1036247359) — Official company press release announcing the NDA completion. - [FDA to review Belite Bio oral therapy for retinal disease with no treatment](https://www.stocktitan.net/news/BLTE/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-xatf1r8p7ar4.html) — Stock Titan coverage of the regulatory milestone. ``` Let's write this note.

Now let's check if there are any watches or threads we need to record or resolve. First, let's look at the watches we can record. 1. For **Amgen's Tavneos FDA Dispute**: - Amgen's submission with the DCRI re-evaluation is due on June 29, 2026. - The public comment period also closes on June 29, 2026. - We should register a `dated_catalyst` watch for June 29, 2026, to monitor the submission of the DCRI review and public docket close. Let's call `record_watch` for this. Let's check if there are any other watches to register. 2. For **Belite Bio's Tinlarebant NDA**: - The 60-day filing review period ends 60 days from June 12, 2026, which is approximately August 11, 2026. - We can register a `dated_catalyst` watch for August 11, 2026, to monitor the FDA's decision on accepting the NDA and assigning a PDUFA date. Let's call `record_watch` for this. 3. For **Jazz/PharmaMar's Zepzelca second-line FDA discussion**: - Jazz said it will discuss next steps with the FDA regarding the post-marketing requirements for Zepzelca's second-line indication following the LAGOON failure. This is an ongoing/one-shot live process. Let's record a watch for an FDA decision/update on Zepzelca's second-line accelerated approval. Let's set it as a `live_process` watch. Let's register these watches. Let's start with Tavneos.

Now let's register the watch for Belite Bio's tinlarebant NDA acceptance.

Now let's register the watch for Jazz's Zepzelca second-line accelerated approval status.

Excellent. Let's make sure we registered everything cleanly. Wait, let's review if there are any threads to resolve. Let's see the open threads we listed from `list_threads`: - None of the open threads directly match the new findings we just wrote. - Let's check `list_threads` again to make sure. - No thread was open for Zepzelca, Belzutifan, Tavneos, or Belite Bio. - Wait, what about the screwworm thread? - `USDA $750M sterile screwworm fly facility operational launch in Texas` (id: `019ec32d-6d1a-725d-9d28-251b38e8d928`). The trigger is "Fires when the USDA's new sterile fly facility in Texas begins operations." - Since the facility just broke ground on April 17, 2026, and is not yet operational, this watch/thread remains open and ongoing. - So there are no threads to resolve this cycle. I will now call `finish_cycle` to complete this research cycle. Let's double check if there are any other actions needed. No, we've successfully written 6 findings (including 2 updates to existing findings and 4 brand new findings on major recent science/health events) and registered 3 new watches. This is a very successful, high-quality, and evidence-grounded research cycle! Let's call `finish_cycle`.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and updates recorded during this cycle: ### 1. Outbreak Updates & Public Health Moves * **New World Screwworm Outbreak Escalates (`[[new-world-screwworm-us-outbreak]]`):** The outbreak of the destructive flesh-eating screwworm (*Cochliomyia hominivorax*) has escalated to seven confirmed cases across Texas and New Mexico. In response, the USDA opened the newly modernized Knipling-Bushland U.S. Livestock Insects Research Laboratory in Kerrville, Texas in May 2026, where scientists have developed a breakthrough "Novo fly" strain which allows for the exclusive production of sterile males (doubling release capacity). Additionally, the USDA and U.S. Army Corps of Engineers broke ground on a $750 million sterile fly production facility at Moore Air Base in Edinburg, Texas on April 17, 2026. * **Bundibugyo Ebola Outbreak (`[[bundibugyo-ebola-outbreak-drc-uganda]]`):** As of June 12, 2026, the outbreak has reached 695 confirmed cases and 138 confirmed deaths across the DRC and Uganda. The DRC remains the epicenter with 676 confirmed cases (mostly in Ituri province). Uganda's situation has stabilized with no new cases reported since June 5 (holding at 19 cases, 2 deaths). Meanwhile, Uganda has criticized foreign air travel restrictions as "unfair." ### 2. Major Drug Approvals & Regulatory Decisions * **FDA Approves Welireg + Keytruda Combo (`[[belzutifan-keytruda-adjuvant-ccrcc-fda]]`):** On June 12, 2026, the FDA approved Merck's Welireg (belzutifan), a first-in-class oral HIF-2α inhibitor, in combination with Keytruda (or its subcutaneous formulation Keytruda Qlex) for the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) post-surgery. This first-ever adjuvant HIF-2α approval is backed by the Phase 3 LITESPARK-022 trial, which demonstrated a 28% reduction in the risk of recurrence, metastasis, or death (DFS HR 0.72). * **Jazz/PharmaMar's Zepzelca Fails Phase 3 LAGOON Trial (`[[zepzelca-phase3-lagoon-sclc-failure]]`):** On June 12, 2026, Jazz Pharmaceuticals and PharmaMar announced that Zepzelca (lurbinectedin) failed its confirmatory Phase 3 LAGOON trial in second-line small cell lung cancer (SCLC). Zepzelca monotherapy actually performed worse than the control chemotherapy arm (median OS of 8.7 months vs. 10.7 months, HR 1.190). This failure places Zepzelca's second-line accelerated approval in jeopardy, though it does not affect its full 2025 approval as a first-line maintenance therapy. ### 3. Emerging Regulatory Disputes & Pipeline Milestones * **Amgen and FDA Clash Over Tavneos (`[[amgen-tavneos-fda-scrutiny-withdrawal-dispute]]`):** Amgen is disputing an FDA proposal to withdraw approval for Tavneos (avacopan). The FDA alleges that ChemoCentryx (acquired by Amgen in 2022) manipulated clinical data in the pivotal Phase 3 ADVOCATE trial and failed to disclose altered patient outcomes, while also raising alarms over 76 serious liver injury cases (including 8 deaths). Amgen has tapped the Duke Clinical Research Institute (DCRI) for an independent re-evaluation of the data, with a high-stakes submission and public docket deadline set for June 29, 2026. * **Belite Bio Completes Tinlarebant NDA (`[[belite-bio-tinlarebant-stargardt-disease-nda]]`):** On June 12, 2026, Belite Bio completed its rolling NDA submission to the FDA for tinlarebant under Breakthrough Therapy Designation. Tinlarebant is an oral retinol binding protein 4 (RBP4) antagonist designed to be the first approved therapy for Stargardt disease type 1 (STGD1), a rare inherited retinal disease affecting 53,000 Americans. ### 4. Registered Watches * **`Amgen Tavneos FDA hearing submission and public docket close`** (Dated Catalyst, expected June 29, 2026) to track the DCRI data submission and docket closure. * **`FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant`** (Dated Catalyst, expected August 11, 2026) to monitor the FDA's 60-day filing decision. * **`FDA regulatory decision on Zepzelca's second-line SCLC indication`** (Live Process) to track the final regulatory outcome of Zepzelca's second-line accelerated approval.